StocksDiva Bio Bin

[PoemStone]

AVMXY 04-05-2012 Avita Medical Granted European Patent Covering Platform Technology
http://finance.yahoo.com/news/avita-medical-granted-european-patent-133000292.html


NORTHRIDGE, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--

Avita Medical Ltd. (ASX:AVH) (OTCQX:AVMXY), the regenerative medicine company, has been granted European patent EP1357922B1 “Cell Suspension Preparation Technique and Use” by the European Patent Office. The patent covers broad claims related to the preparation of a cell suspension comprised of the patient’s own epithelial cells (autologous suspension), the therapeutic use of the cell suspension and, importantly, a ‘composition of matter’ claim wherein the actual suspension of autologous cells is covered.

The patented technology is incorporated into the company’s flagship regenerative product, ReCell® Spray-On Skin®, used in the treatment of chronic and acute wounds and a wide range of reconstructive and aesthetic procedures.

ReCell is a stand-alone, point-of-care device that allows

the harvesting of a small sample of a patient’s own skin and, via a proprietary enzymatic and mechanical process, the disaggregation of the constituent cells;
the incorporation of the disaggregated and isolated cells into a suspension consisting of mature and immature epithelial cells as well as undifferentiated skin cells; and
the delivery and application of this therapeutic cellular suspension to the patient.
Each of these aspects is covered by the granted patent.

The intellectual property covered under the patent expands and strengthens Avita’s existing patented technology. The company is continuing to build its intellectual property estate with a widening range of potential products and applications.

In related news, the US Patent and Trademark Office has awarded Avita the registration for the trademark “Spray-On Skin®”, US Trademark Registration No 4072126.

“ReCell is a platform technology with immense market potential,” said Avita Medical CEO, Dr William F Dolphin. “This patent grant further validates Avita’s unique capabilities in harnessing the body’s ability to heal itself and to regenerate damaged tissue. The patent secures additional protection for our intellectual property in the rapidly growing field of regenerative medicine. Moreover, securing the registered trademark ‘Spray-On Skin’ reinforces the company’s global branding as ReCell increases its presence in worldwide markets.”

ABOUT AVITA MEDICAL LTD.

Avita Medical (www.avitamedical.com) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. The company’s lead product, ReCell® Spray-On SkinTM, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited to investigational use.